To overcome the challenge of low MUC16 expression on ovarian cancer cells, MUC16-specific CAR-T cells were engineered to secrete a bispecific T cell engager that targets WT1, enabling the CAR-T cells to kill ovarian cancer cells via an orthogonal mechanism. This evidence concerns the gene WT1 and ovarian carcinoma.